688687.SHG Beijing Kawin Technology Share-holding Co Ltd
- Market cap
- CNY 2.81B
- P/E
- -
- P/B
- 1.55x
- ROE
- 3.1%
- Dividend yield
- 2.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688687.SHG undervalued?
Graham numberThe Graham number of Beijing Kawin Technology Share-holding Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Kawin Technology Share-holding Co Ltd fundamental analysis
No fundamental analysis for Beijing Kawin Technology Share-holding Co Ltd yet.
Beijing Kawin Technology Share-holding Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Kawin Technology Share-holding Co Ltd
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhizin tablets, capsules, and injections; and pirfenidone tablets for mild to modera…
Full company profileBeijing Kawin Technology Share-holding Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Kawin Technology Share-holding Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 268M | 491M | 706M | 825M | 862M | 1.14B | 1.16B | 1.41B | 1.23B | 1.32B | 954M |
| Gross Profit | 195M | 412M | 607M | 719M | 747M | 1.00B | 1.00B | 1.18B | 1.01B | 1.09B | 744M |
| Operating Income | 23.1M | 27.8M | 49.2M | 67.3M | 88.7M | 131M | 106M | 171M | 193M | 63.2M | 77.1M |
| EBITDA | 48.0M | 51.3M | 71.3M | 89.9M | 121M | 159M | 135M | 185M | 221M | 63.2M | 79.1M |
| Net Income | 23.9M | 26.8M | 44.9M | 53.6M | 75.6M | 107M | 83.4M | 117M | 142M | 29.6M | 53.5M |
| EPS | 0.24 | 0.23 | 0.37 | 0.44 | 0.59 | 0.66 | 0.49 | 0.70 | 0.85 | 0.17 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 695M | 724M | 815M | 1.05B | 1.17B | 2.18B | 2.21B | 2.45B | 2.62B | 2.79B | 2.57B |
| Total Liabilities | 149M | 111M | 160M | 281M | 319M | 490M | 528M | 663M | 735M | 1.05B | 832M |
| Shareholders' Equity | 533M | 609M | 655M | 772M | 848M | 1.68B | 1.68B | 1.75B | 1.84B | 1.71B | 1.71B |
| Cash & Short-term Investments | 190M | 246M | 256M | 358M | 420M | 1.24B | 1.24B | 1.22B | 1.25B | 834M | 649M |
| Total Debt | 70.9M | - | - | - | - | 3.42M | 15.6M | 53.4M | 246M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 8.13M | 14.2M | 60.3M | 103M | 131M | 118M | 134M | 127M | 104M | 110M | - |
| Capital Expenditure | 77.0M | 56.4M | 50.7M | 49.1M | 41.6M | 44.0M | 75.0M | 155M | 267M | 134M | 40.0M |
| Free Cash Flow | -68.9M | -42.2M | 9.65M | 53.9M | 89.9M | 74.0M | 59.0M | -28.1M | -162M | -23.7M | -25.7M |
| Ratios | |||||||||||
| ROE | 4.5% | 4.4% | 6.8% | 6.9% | 8.9% | 6.4% | 5.0% | 6.6% | 7.7% | 1.7% | 3.1% |
| ROA | 3.4% | 3.7% | 5.5% | 5.1% | 6.4% | 4.9% | 3.8% | 4.8% | 5.4% | 1.1% | 2.1% |
| Net Profit Margin | 8.9% | 5.5% | 6.4% | 6.5% | 8.8% | 9.4% | 7.2% | 8.3% | 11.6% | 2.2% | 5.6% |
| Debt to Equity | 0.13x | - | - | - | - | 0.00x | 0.01x | 0.03x | 0.13x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Kawin Technology Share-holding Co Ltd dividends
- Dividend yield
- 2.00%
- Forward dividend
- 0.25 CNY
- Payout ratio
- 189.1%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 56.0M | 0.32 | 189.1% |
| 2024 | CNY 44.9M | 0.27 | 31.5% |
| 2023 | CNY 33.5M | 0.20 | 28.7% |
| 2022 | CNY 42.6M | 0.25 | 51.1% |
| 2021 | CNY 25.5M | 0.16 | 23.7% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | 1.27M | 0.01 | 4.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Beijing Kawin Technology Share-holding Co Ltd
- Insiders 30.51%
- Institutions 0.71%
- Public & others 68.78%
- Shares outstanding 171M
- Free float 121M
Beijing Kawin Technology Share-holding Co Ltd company profile
- Company name
- Beijing Kawin Technology Share-holding Co Ltd
- Ticker
- 688687.SHG
- ISIN
- CNE1000054C3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 617
- Fiscal year end
- December
- Address
- Building 3, No. 6, Rongjing East Street, Beijing, China, 100176
- Phone
- 86 10 8712 0888
- Website
- kawin.com.cn
About Beijing Kawin Technology Share-holding Co Ltd
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhizin tablets, capsules, and injections; and pirfenidone tablets for mild to moderate idiopathic pulmonary fibrosis. It is also involved in contract manufacture organization/contract development and manufacturing organization; technology and biotechnology development and consulting; technology promotion and application; and wholesale of pharmaceutical. Beijing Kawin Technology Share-Holding Co., Ltd. was incorporated in 2008 and is based in Beijing, China.
Beijing Kawin Technology Share-holding Co Ltd management
10- Mr. Desheng ZhouPresident & Chairman of the Board · born 1971
- Ms. Hong Juan LiuChief Financial Officer · born 1976
- Mr. Zhan WangVP, Board Secretary & Chief Human Resources Officer · born 1981
- Ms. Huan WangExecutive VP & Director · born 1979
- Mr. Jifeng ShiVP, Chief Research Officer, Core Technical Personnel & Director · born 1974
- Mr. Zhenqiang DuVice President · born 1976
- Mr. Jian TangVice President · born 1978
- Ms. Xiao XuVice President · born 1974
- Xiao Qing LiAccounting Supervisor
- Ms. Shan LiuHead of Antibody Drug Development Department & Core Technical Personnel · born 1988